Author

Philip Wastall

Observed name: P. Wastall

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Pfizer (United Kingdom), Bristol-Myers Squibb (United States)

OpenAlex ID: A5037819084

The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data

1997 · R. Scott Obach, James G. Baxter, et al. · Journal of Pharmacology and Experimental Therapeutics · 982

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils

2016 · Todd G. Kirchgessner, Paul Sleph, et al. · Cell Metabolism · 173

Comparative human pharmacokinetics and metabolism of single‐dose oral and intravenous sildenafil

2002 · Gary J. Muirhead, David J. Rance, et al. · British Journal of Clinical Pharmacology · 121

A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects

2012 · Jessie Wang, Yan Song, et al. · Thrombosis and Haemostasis · 54

Assessment of Drug-Drug Interactions between Daclatasvir and Methadone or Buprenorphine-Naloxone

2015 · T. Garimella, R. Wang, et al. · Antimicrobial Agents and Chemotherapy · 30

Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone

2014 · Tushar Garimella, Reena Wang, et al. · Journal of the International AIDS Society · 8

Modipafant, a new PAF antagonist: pharmacokinetics and disposition in rat, dog and man

1996 · S. G. Jezequel, S. Uden, et al. · Xenobiotica · 7

Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects

2015 · Dawei Xuan, Scott McBride, et al. · Clinical Pharmacology in Drug Development · 3

1166Evaluation of Drug-Drug Interaction between Daclatasvir and Methadone or Buprenorphine/Naloxone

2014 · Tushar Garimella, Reena Wang, et al. · Open Forum Infectious Diseases

Works count: 9

Citation count: 1,378

H-index: 7

I10-index: 5